Sivik Global Healthcare LLC Makes New Investment in Repligen Corporation $RGEN

Sivik Global Healthcare LLC bought a new stake in Repligen Corporation (NASDAQ:RGEN) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 20,000 shares of the biotechnology company’s stock, valued at approximately $3,845,000. Repligen comprises 2.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 20th largest position.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. NorthCrest Asset Manangement LLC purchased a new stake in shares of Repligen in the 3rd quarter worth $477,000. GK Wealth Management LLC purchased a new stake in Repligen in the third quarter worth about $163,000. GAMMA Investing LLC increased its position in Repligen by 16.7% in the third quarter. GAMMA Investing LLC now owns 2,269 shares of the biotechnology company’s stock worth $436,000 after buying an additional 325 shares in the last quarter. Farther Finance Advisors LLC increased its position in Repligen by 35.5% in the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock worth $72,000 after buying an additional 98 shares in the last quarter. Finally, CoreCap Advisors LLC raised its stake in shares of Repligen by 1,275.0% in the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock worth $53,000 after buying an additional 255 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RGEN has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Barclays boosted their price objective on Repligen from $175.00 to $225.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings raised shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday. Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. Finally, UBS Group restated a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Repligen Price Performance

Shares of RGEN traded up $5.00 during mid-day trading on Tuesday, hitting $177.51. 408,085 shares of the stock were exchanged, compared to its average volume of 1,043,482. The company has a market cap of $10.02 billion, a PE ratio of 242.55, a price-to-earnings-growth ratio of 3.17 and a beta of 1.08. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $198.87. The firm has a 50-day moving average of $174.23 and a two-hundred day moving average of $143.90. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the firm posted $0.26 earnings per share. Repligen’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.